Open in interactive viewer → charts, metric popovers & call review

SANUWAVE: A 21% Medicare Cut, a $15 Million Market Cap, and a CEO Calling It an Invitation

Capital sales fell 73%, the used-system glut is eating new placements, and management quietly retired the one metric that used to explain the installed base.
SNWV · Earnings Call · 2026-11-11

The tape already voted

SANUWAVE's shares peaked at $12.13 on 14 July 2026 — the exact day, by the CEO's own telling, that the CMS proposed rule for 2027 dropped. From that high to the 11 November print the stock has surrendered 85%, and roughly two-thirds of that damage came in the final nine trading sessions around the call. The whole enterprise is now worth $15.3 million. Price-to-revenue has compressed from 7.8x to 2.1x in a year. That is the backdrop against which Morgan Frank opened the third-quarter call with a sentence that tells you everything about the quarter: “Q3 was really the story of the CMS proposed rule.” — Morgan Frank, Chairman and CEO · 2026-11-11 This is a company whose stock chart is now a reimbursement chart.

What actually broke

Revenue for the quarter was $8.6 million, down 24% from $11.3 million. The culprit was not the recurring business — it was capital equipment. UltraMIST system revenue fell roughly 73% to $1.2 million on a 74% unit decline, and system placements collapsed from 82 in Q2 to 40 in Q3, producing the quarter's strangest artifact: sixty new customers added while only forty systems shipped. Crucially, this is a *fresh* break, not a slow bleed. The last filed numbers (Q2, filed 6 August) showed total revenue of $10 million, up 4% year over year. One regulatory proposal later, the entire commercial model went sideways. Gross margin held at 77.3% — the mix shift toward consumables is a margin headwind, not a catastrophe — but it was enough to swing operating income from +$0.9 million to a $1.1 million loss and cut adjusted EBITDA from $3.2 million to $0.7 million. The balance sheet is the clock. Cash stood at $6.6 million against an effective net cash position of about -$10 million, after $4.3 million of scheduled term-loan principal and $2.7 million of sales-tax remittances year-to-date. And the 10-Q disclosed a covenant breach: “we were not in compliance with the fixed charge coverage ratio under our JPMorgan credit agreement as of September 30,” — Peter Sorensen, CFO · 2026-11-11 since waived by amendment on 28 October. The voluntary disclosure agreements process is now a cash-flow item as much as a legal one — the CFO noted several settlements landed *below* previously accrued balances, which is the quarter's only quiet positive.

The metric management stopped sharing

Here is the most telling line in the prepared remarks. After describing customer exits, practitioner reductions and used-equipment purchases, Frank said: “we're simply not confident that it has the resolution to be worth sharing right now.” — Morgan Frank, Chairman and CEO · 2026-11-11 The active systems number — a metric this management team has leaned on for several quarters, and one of its biggest keyword gainers as recently as Q1 2026 — has been retired from the disclosure set precisely when it would be most informative. The mechanism behind the mess is used systems flooding the secondary market as smaller wound-care operators shut down. Those cannibalized new-box sales, and management will not forecast how long the overhang lasts: "I suspect it will be a factor in Q4." This question is not new — an investor asked on the March 2026 call whether SANUWAVE could buy back and recondition discontinued units, and got

It's — possibly. I don't want to -- given some things going on, I don't want to talk in too much specificity about that. But we've certainly had a similar thought.

Morgan Frank, Chief Executive Officer · 2026-03-27
Three calls, one unresolved problem, now compounding. Meanwhile the recurring core is genuinely alive: applicator revenue rose 2% on 15% higher unit volume, offset by an 11% lower ASP from higher mix of reseller sales. That wholesale channel is cheaper to serve and carries a better fall-through margin, per prior commentary — but it means volume growth and revenue growth have decoupled. Utilization is fine. Price realization is not.

The bull case is now a reimbursement argument

Strip out the spin and the CMS final rule was two-thirds bad, one-third genuinely interesting. The physician fee schedule payment for CPT 97610 falls to $314.54 in 2027 from $397.81 — the reimbursement rate cut that has defined the last two quarters. But the hospital outpatient rate rose roughly 14%, to $235.04 from $204.98. And the 97610 code shed its Q1 status indicator in favor of T, meaning it can now be billed alongside other procedures rather than packaged to zero. More than half of 2025 HOPD treatments were packaged, and management's read is that those zeroed claims skewed toward the most complex wounds. That is the seed of the argument to the AMA RUC and CMS for scaling factors in the 2028 rule — code structure that accounts for wound depth, size, quantity and site. The CEO's framing is worth quoting because it is either the smartest read in the sector or the most elaborate cope: “this actually seems like an invitation to help restructure this code into something that is better aligned with the reality of use cases.” — Morgan Frank, Chairman and CEO · 2026-11-11 The market, sitting 85% below the July high, is not pricing an invitation. The strategic pivot to hospitals — restructured sales force, HAPI as a "$27 billion market," up from the $22 billion figure cited in October 2025 — is real but slow, and the CEO concedes the sales cycle for value committees is long. When an analyst asked about consolidation, the answer was a polite retreat: “we're much more focused on partnership than M&A.” — Morgan Frank, Chairman and CEO · 2026-11-11 What ties it together is a company that spent 2026 promising acceleration and delivering a regulator. In May the CEO was pointing to a second half that historically runs 48% above the first half; in March he said he'd have "a lot better ability to speak to that when we report Q1." Those guideposts are gone now, replaced by an argument about the 2028 Medicare rule. The applicator base — growing units, growing utilization — is the asset. The reimbursement code is the hostage. And with $6.6 million of cash and a waived covenant, the clock runs only as far as July 2027, when the next proposed rule is published.